Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Project Grant

McMaster University

$248,624.00

Comparison of Anti-coagulation and anti-Platelet Therapies for Intracranial Vascular Atherostenosis (CAPTIVA)

FY 2023-24

Summary
CAPTIVA aims to improve the care of patients who have suffered a stroke due to the narrowing of blood vessels in the brain. This type of stroke is common and has a high risk of recurrence. When someone has a stroke from narrowing of brain blood vessels, we treat them with aspirin and clopidogrel (blood thinning drugs) or aspirin alone to prevent another stroke. However, even with these treatments, there is a very high risk of having another stroke (1 in 5 chance in one year). Therefore, better treatment for this devastating disease is necessary. We have shown that, in patients with narrowing of blood vessels elsewhere in the body, adding low-dose rivaroxaban (blood thinning drug) to aspirin caused a 50% reduction of stroke. In addition, a smaller study (CATIS-ICAD) that included 100 patients, showed that aspirin+low-dose rivaroxaban is safe in strokes due to the narrowing of brain blood vessels. Another study showed the combination of ticagrelor (blood thinning drug) and aspirin to be more effective for preventing recurrent strokes than clopidogrel and aspirin. Therefore, CAPTIVA aims to look for the effectiveness of asprin+low-dose rivaroxaban and aspirin+ticagrelor compared to aspirin + clopidogrel in a larger trial of 1,683 patients, including 280 Canadians. This trial is a randomized controlled trial (RCT). RCTs are the most reliable studies of treatments. Patients with a stroke due to narrowing of brain blood vessels that occurred within 30 days will be assigned randomly, with a 1 in 3 chance of receiving one of these combinations. We will follow patients for one year to monitor for new strokes. The number of strokes in each group will be monitored closely by a separate panel of doctors to ensure the safety of patients in the study. The results of CAPTIVA will have the potential to substantially improve the health of around 1,875,000 people yearly, who survive an ischemic stroke due to the narrowing of blood vessels of the brain.
Program
Project Grant
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
501808
Name
Perera Kanjana S
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Clinical
Prcname2
Clinical Investigation - D: Cardiovascular Systems
Projecttitle
Comparison of Anti-coagulation and anti-Platelet Therapies for Intracranial Vascular Atherostenosis (CAPTIVA)
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$248,624
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Captiva; Compass Regime; Icas; Intracranial Stenosis; Ischemic Stroke; Prevention
Abstract
CAPTIVA aims to improve the care of patients who have suffered a stroke due to the narrowing of blood vessels in the brain. This type of stroke is common and has a high risk of recurrence. When someone has a stroke from narrowing of brain blood vessels, we treat them with aspirin and clopidogrel (blood thinning drugs) or aspirin alone to prevent another stroke. However, even with these treatments, there is a very high risk of having another stroke (1 in 5 chance in one year). Therefore, better treatment for this devastating disease is necessary. We have shown that, in patients with narrowing of blood vessels elsewhere in the body, adding low-dose rivaroxaban (blood thinning drug) to aspirin caused a 50% reduction of stroke. In addition, a smaller study (CATIS-ICAD) that included 100 patients, showed that aspirin+low-dose rivaroxaban is safe in strokes due to the narrowing of brain blood vessels. Another study showed the combination of ticagrelor (blood thinning drug) and aspirin to be more effective for preventing recurrent strokes than clopidogrel and aspirin. Therefore, CAPTIVA aims to look for the effectiveness of asprin+low-dose rivaroxaban and aspirin+ticagrelor compared to aspirin + clopidogrel in a larger trial of 1,683 patients, including 280 Canadians. This trial is a randomized controlled trial (RCT). RCTs are the most reliable studies of treatments. Patients with a stroke due to narrowing of brain blood vessels that occurred within 30 days will be assigned randomly, with a 1 in 3 chance of receiving one of these combinations. We will follow patients for one year to monitor for new strokes. The number of strokes in each group will be monitored closely by a separate panel of doctors to ensure the safety of patients in the study. The results of CAPTIVA will have the potential to substantially improve the health of around 1,875,000 people yearly, who survive an ischemic stroke due to the narrowing of blood vessels of the brain.
Competitiondate
202403
Approvedterm2
4 yrs 0 mth
Pinamesdelim
Perera, Kanjana S; Chimowitz, Marc; Hoh, Brian
Approvedterm
4 ans 0 mois
Cihrcontribution2
~ $248,624~ $0~
McMaster University - $248,624 Grant (2023-24) | Canada Spends